IMPACT Therapeutics Licenses PARP Inhibitor Senaparib to Pharmanovia in Deal Worth Up to €423.5 Million
核心洞察
IMPACT Therapeutics (搜索) has signed an exclusive licensing agreement with Pharmanovia for senaparib across 66 countries including Europe, MENA, Australia, and New Zealand.
The deal includes up to €423.5 million in total consideration, comprising upfront, regulatory milestone, and commercial milestone payments, plus tiered royalties up to the mid-twenties percent.
Senaparib's European Marketing Authorisation Application was accepted by the EMA in August 2025, with approval expected in the second half of 2026.
IMPACT Therapeutics (搜索), a Shanghai-based commercial-stage biotechnology company, announced on July 31, 2026, that it has entered into an exclusive licensing agreement with Pharmanovia, a global specialty pharmaceutical company, granting Pharmanovia exclusive rights to manufacture, develop, and commercialize senaparib across Europe, the Middle East and North Africa, Australia, and New Zealand.
The agreement covers senaparib as maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy.
Financial Terms and Deal Structure
Under the terms of the exclusive partnership, IMPACT is eligible to receive total consideration of up to €423.5 million, comprising an upfront payment, near-term regulatory milestones, and commercial milestone payments tied to achieving certain sales thresholds. In addition, IMPACT will receive tiered royalties up to the mid-twenties percent on product net sales.
The agreement spans 66 countries, including all 27 European Union member states, the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and countries in the Middle East and North Africa.
Regulatory Progress and Timeline
Senaparib's Marketing Authorisation Application for first-line maintenance therapy in adult patients with advanced ovarian cancer (搜索) was formally accepted by the European Medicines Agency in August 2025. EMA approval is anticipated in the second half of 2026.
The drug has already achieved significant regulatory milestones in China. Senaparib capsules received approval from the National Medical Products Administration in January 2025 as a first-line maintenance therapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, and were subsequently included in China's National Reimbursement Drug List in December 2025. The product became reimbursable for ovarian cancer (搜索) first-line "all-comers" as of January 1, 2026.
Clinical Profile of Senaparib
Senaparib (IMP4297) is a novel, highly potent PARP1/2 (搜索) inhibitor independently developed by IMPACT Therapeutics (搜索). According to the company, its unique molecular structure ensures excellent target selectivity and a wide safety window. IMPACT states that senaparib delivered the most favorable progression-free survival outcome among PARP1/2 inhibitors — on a non-head-to-head basis — for first-line maintenance therapy in ovarian cancer (搜索) "all-comers" in China.
Strategic Significance
The exclusive partnership represents IMPACT's first step in bringing its validated treatment options to patients outside of China. "By leveraging Pharmanovia's specialist expertise and established infrastructure, we expect senaparib to reach target patients in the collaboration territories more quickly following approval, helping to deliver high-quality treatment options to address unmet medical needs," IMPACT stated in the announcement.
IMPACT Therapeutics (搜索), founded in 2009, focuses on advancing synthetic lethality-based precision anti-cancer therapies. The company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on May 13, 2026. IMPACT is one of only three companies worldwide with both commercial-stage PARP1/2 (搜索) inhibitors and clinical-stage next-generation PARP1 (搜索)-selective inhibitors. Beyond senaparib, the company's pipeline includes PARP1-selective inhibitors IMP1734 and IMP1707 (co-developed with Eikon Therapeutics), an ATR inhibitor (IMP9064), a WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors.
Pharmanovia is a global specialty pharmaceutical company that partners with innovative biotech and large pharma companies to bring specialty medicines to patients, combining scientific, medical, regulatory, market access, supply chain, and commercial expertise.